Abiopharma

🔍 Napoli Silvio (Director)

Company: Lucid Group, Inc. (LCID)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 402,073 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 402,073.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,000,000 shares of Employee Stock Option (right to buy) at $8.21 per share (Derivative)
  Date: 2026-04-15 | Code: A | Expires: 2036-04-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units that will vest over four years, with 1/4th vesting on June 5, 2027 and 1/16th vesting quarterly thereafter in twelve installments, on each March 5, June 5, September 5, and December 5 of each calendar year that occurs following June 5, 2027, subject to the reporting person's continued employment with the Issuer or its subsidiary through each vesting date.
• F2: Represents performance-based stock options that are divided into five tranches and subject to both time-based and performance-based vesting conditions. A given tranche vests upon the later of (x) the tranche's time-based vesting date (which is April 15, 2028 for tranche 1, April 15, 2029 for tranches 2 and 3 and April 15, 2030 for tranches 4 and 5) and (y) certification of achievement of the market capitalization performance hurdle applicable to the tranche ($5.0 billion, $7.5 billion, $10.0 billion, $12.5 billion, and $17.5 billion for tranches 1,2,3,4, and 5 respectively, calculated in accordance with the reporting person's stock option agreement), in each case, subject to the reporting person's continued employment with the Issuer or its subsidiary through each vesting date.